Medical Disclaimer: This guide is for educational purposes only. It does not constitute medical advice. All GLP-1 treatment decisions, dosing, and eligibility determinations are made by a licensed provider based on your individual health history. Results vary by patient.
The Science, Simply
What GLP-1 Medications Actually Do
GLP-1 receptor agonists act on pathways involved in appetite and food intake and can delay gastric emptying. Tirzepatide also acts on GIP receptors. Research published in Diabetes, Obesity and Metabolism reported reduced food cravings with semaglutide in a small trial; this does not guarantee that food noise will disappear.
Unlike older weight-loss approaches that required extreme willpower, GLP-1 medications work at a biological level. The goal isn't to make you eat less through suffering — it's to rebalance the signals driving overconsumption in the first place.
Week by Week
What to Expect, Month by Month
Every patient's timeline is different. This is a general guide based on the most common clinical patterns. Your provider will customize based on your response.
- Your provider establishes your starting dose — this is intentionally low
- Nausea is common but not inevitable; report severe or persistent symptoms promptly
- Eat smaller, slower meals — large meals amplify nausea at first
- Discuss an appropriate fluid target, especially if you have a fluid restriction
- Do not skip your injection day; consistency matters for tolerance
- Changes in food-related thoughts vary; there is no established week-by-week response
- Discuss appetite changes and tolerability with your provider
- Continue logging how you feel — your provider reviews this
- Ask your provider or dietitian to personalize protein intake and activity
- Report persistent nausea promptly; do not wait until week 4 if symptoms are concerning
- Your provider may recommend a dose increase based on your tolerance and results
- Weight changes vary widely — compare to your own baseline, not others'
- Introduce activity at a level that is safe for your health and current symptoms
- Some patients experience a plateau — this is normal and manageable
- Follow-up check-ins with your provider are important at this stage
- Maintenance dosing depends on the product, tolerance and your provider's assessment
- Continue discussing nutrition, appetite and food-related concerns
- Your provider will help you evaluate long-term use vs. tapering options
- Strength training becomes highly beneficial at this stage
- Celebrate non-scale victories: energy, sleep quality, mental clarity
Be Prepared
Common Side Effects & How to Manage Them
Most side effects are mild, temporary, and manageable. Here's what to expect and how to handle it.
Eat smaller meals slowly and avoid foods that worsen symptoms. Contact your provider for severe or persistent nausea; there is no guaranteed resolution date.
Fatigue can have several causes. Discuss persistent or worsening symptoms, food intake and hydration with your provider.
Maintain appropriate hydration and introduce fiber and activity as tolerated. Seek advice for persistent constipation or severe abdominal symptoms.
This is the medication working. Still aim for your protein targets even if you're not hungry — muscle preservation depends on it.
Follow the storage and injection instructions for your specific product, rotate injection sites and report worsening redness or swelling.
Headache has several possible causes. Discuss hydration and persistent symptoms with your provider; seek prompt care for a severe or sudden headache.
You experience severe abdominal pain, persistent vomiting, signs of allergic reaction (rash, swelling, difficulty breathing), vision changes, or severe persistent headache. These are rare but require prompt medical attention.
Nutrition
What to Eat on GLP-1 Medication
Appetite suppression changes what you eat. Here's how to make the most of it without losing muscle.
- 80–100g protein daily minimum
- Chicken, fish, eggs, Greek yogurt
- Protein shake if appetite is very low
- Protein first at every meal
- Smaller, lighter meals
- Avoid greasy or spicy foods
- Cold foods often feel better
- Ginger tea can ease nausea
- 64+ oz water every day
- Fiber from vegetables
- Limit alcohol
- Don't skip meals entirely
Last reviewed: June 2026 · Medical content is for educational purposes only and is not a substitute for professional medical advice.
Ready to Find Out If You Qualify?
Every South Florida Trim Clinic patient is reviewed by a licensed provider. Start with a free telehealth consultation — no obligation, no pressure.
Naples-based telehealth · Serving Florida & 47 of 50 states (excluding AK, HI, AR) · Medication starts at $149/month · Results vary
MEDICAL SOURCES & FURTHER READING
Check the source and its limits. The notes below explain which medical information each reference supports; they are not patient-specific advice or evidence of this clinic's results.
- Wegovy (semaglutide) injection — prescribing information
Sections 1–6 and the Medication Guide cover eligibility, dose escalation, GLP-1 action, gastrointestinal effects, thyroid-tumor warnings, pancreatitis, gallbladder disease, volume depletion and pregnancy precautions.
Evidence limits: This dated label is for FDA-approved Wegovy injection. Follow the current label for your specific product and your prescriber's instructions; it does not establish the safety or effectiveness of a compounded preparation.
- Zepbound (tirzepatide) injection — prescribing information
Sections 1–6 and 12 describe GIP/GLP-1 receptor activity, eligibility, gradual dose escalation, common adverse reactions, contraindications and important safety warnings. Section 8 addresses pregnancy and oral contraceptive precautions.
Evidence limits: Applies to the approved Zepbound product, not every tirzepatide preparation. Trial adverse-event frequencies are product- and population-specific.
- Prescription Medications to Treat Overweight & Obesity
Explains provider assessment, BMI and health considerations, medication mechanisms, use alongside nutrition and activity, treatment duration and possible weight regain after stopping.
Evidence limits: General education, not a determination of any patient's eligibility or an endorsement of this clinic.
- Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
This published clinical advisory discusses adequate nutrition and hydration, individualized protein intake, gastrointestinal symptom management, resistance exercise, muscle function and nutrient-deficiency screening during GLP-1 treatment.
Evidence limits: A literature-informed advisory, not a trial proving a particular meal plan, universal protein/fluid target, or guaranteed muscle preservation. The source includes a linked 2026 correction.
- Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
Research published in Diabetes, Obesity and Metabolism reported lower hunger and food cravings and better control of eating in a 30-person, 12-week crossover trial of semaglutide titrated to 1 mg.
Evidence limits: A small, short trial with manufacturer involvement. It did not establish a diagnosis called food noise, prove addiction treatment, or guarantee that intrusive thoughts disappear on a set schedule.
- Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Research published in Diabetes, Obesity and Metabolism reported substantial average regain in 327 participants during the year after semaglutide and the structured lifestyle intervention were stopped.
Evidence limits: Exploratory extension funded by Novo Nordisk. Both medication and structured lifestyle intervention ended; it does not prove a tapering strategy prevents regain or that every patient will regain the same amount.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Research published in the New England Journal of Medicine reported fewer major cardiovascular events with semaglutide 2.4 mg than placebo among adults aged at least 45 with established cardiovascular disease and overweight or obesity, without diabetes.
Evidence limits: SELECT was funded by Novo Nordisk. This selected high-risk population does not establish the same benefit for every patient, for tirzepatide, or for compounded preparations.
RESEARCH & REFERENCES
- Wegovy (semaglutide) injection — prescribing information
U.S. Food and Drug Administration. FDA product labeling. 2025.
Read Wegovy (semaglutide) injection — prescribing information - Zepbound (tirzepatide) injection — prescribing information
U.S. Food and Drug Administration. FDA product labeling. 2026.
Read Zepbound (tirzepatide) injection — prescribing information - Prescription Medications to Treat Overweight & Obesity
National Institute of Diabetes and Digestive and Kidney Diseases (NIH). NIDDK patient education. Web resource; accessed 2026.
Read Prescription Medications to Treat Overweight & Obesity - Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
Dariush Mozaffarian and colleagues. Obesity. 2025.
Read Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell and colleagues. Diabetes, Obesity and Metabolism. 2017.
Read Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity - Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
John P. H. Wilding and colleagues. Diabetes, Obesity and Metabolism. 2022.
Read Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension - Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff and colleagues. New England Journal of Medicine. 2023.
Read Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
These independent information sources do not endorse, sponsor or affiliate with South Florida Trim Clinic. Education is not a substitute for individualized medical advice. Prescription treatment requires evaluation by an appropriately licensed healthcare provider.